关注
Gianmarco Mastrogiovanni
Gianmarco Mastrogiovanni
Cambridge Stem Cell Institue
在 cam.ac.uk 的电子邮件经过验证
标题
引用次数
引用次数
年份
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
L Broutier, G Mastrogiovanni, MMA Verstegen, HE Francies, LM Gavarró, ...
Nature medicine 23 (12), 1424-1435, 2017
11992017
Long-term expansion, genomic stability and in vivo safety of adult human pancreas organoids
N Georgakopoulos, N Prior, B Angres, G Mastrogiovanni, A Cagan, ...
BMC developmental biology 20, 1-20, 2020
922020
The plastic liver: differentiated cells, stem cells, every cell?
CJ Hindley, G Mastrogiovanni, M Huch
The Journal of clinical investigation 124 (12), 5099-5102, 2014
332014
RNF43/ZNRF3 loss predisposes to hepatocellular-carcinoma by impairing liver regeneration and altering the liver lipid metabolic ground-state
G Belenguer, G Mastrogiovanni, C Pacini, Z Hall, AM Dowbaj, ...
Nature communications 13 (1), 334, 2022
292022
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation
N Casini, IM Forte, G Mastrogiovanni, F Pentimalli, A Angelucci, ...
Oncotarget 6 (14), 12421, 2015
262015
Loss of RNF43/ZNRF3 predisposes to Hepatocellular carcinoma by impairing liver regeneration and altering liver fat metabolism
G Mastrogiovanni, C Pacini, S Kakava, R Arnes-Benito, CR Bradshaw, ...
bioRxiv, 2020.09. 25.313205, 2020
62020
系统目前无法执行此操作,请稍后再试。
文章 1–6